IkerChem S.L. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 27

IkerChem S.L. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “IkerChem S.L. - Product Pipeline Review - 2012” provides data on the IkerChem S.L.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, IkerChem S.L.’s corporate website, SEC filings, investor presentations and featured press releases, both from IkerChem S.L. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- IkerChem S.L. - Brief IkerChem S.L. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of IkerChem S.L. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of IkerChem S.L. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IkerChem S.L.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate IkerChem S.L.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IkerChem S.L. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IkerChem S.L.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IkerChem S.L..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IkerChem S.L. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of IkerChem S.L.; IkerChem S.L. - Key Therapeutics; IkerChem S.L. - Pipeline Overview and Promising Molecules; IkerChem S.L. - News; IkerChem S.L. - Latest Updates; IkerChem S.L. - Pipeline; IkerChem S.L. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
IkerChem S.L. Snapshot 5
IkerChem S.L. Overview 5
Key Information 5
Key Facts 5
IkerChem S.L. – Research and Development Overview 6
Key Therapeutic Areas 6
IkerChem S.L. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
IkerChem S.L. – Pipeline Products Glance 10
IkerChem S.L. – Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
IkerChem S.L. – Drug Profiles 12
DNMT Inhibitors 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
IKH02 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
IKH25 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
IKH35 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
JMJ Inhibitors 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Proteasome Inhibitors 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IkerChem S.L. – Pipeline Analysis 18
IkerChem S.L. – Pipeline Products by Therapeutic Class 18
IkerChem S.L. – Pipeline Products By Target 19
IkerChem S.L. – Pipeline Products By Mechanism of Action 20
IkerChem S.L. – Locations And Subsidiaries 21
Head Office 21
Financial Deals Landscape 22
IkerChem S.L., Deals Summary 22
IkerChem S.L., Pharmaceuticals & Healthcare, Deal Details 23
Venture Financing 23
IkerChem Raises $1.9 Million In Venture Financing 23
IkerChem Raises $0.34 In Venture Financing Round 24
IkerChem Secures $0.38 Million In Venture Financing 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
IkerChem S.L., Key Information 5
IkerChem S.L., Key Facts 5
IkerChem S.L. – Pipeline by Indication, 2012 7
IkerChem S.L. – Pipeline by Stage of Development, 2012 8
IkerChem S.L. – Monotherapy Products in Pipeline, 2012 9
IkerChem S.L. – Pre-Clinical, 2012 10
IkerChem S.L. – Discovery, 2012 11
IkerChem S.L. – Pipeline By Therapeutic Class, 2012 18
IkerChem S.L. - Pipeline By Target, 2012 19
IkerChem S.L. – Pipeline Products By Mechanism of Action, 2012 20
IkerChem S.L., Deals Summary 22
IkerChem Raises $1.9 Million In Venture Financing 23
IkerChem Raises $0.34 In Venture Financing Round 24
IkerChem Secures $0.38 Million In Venture Financing 25

List of Figures
IkerChem S.L. – Pipeline by Indication, 2012 7
IkerChem S.L. – Pipeline by Stage of Development, 2012 8
IkerChem S.L. – Monotherapy Products in Pipeline, 2012 9
IkerChem S.L. – Pipeline By Therapeutic Class, 2012 18
IkerChem S.L. - Pipeline By Target, 2012 19
IkerChem S.L. - Pipeline Products By Mechanism of Action, 2012 20

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• TeliaSonera: Transforming its Business